Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany. The Company is also focused on regulatory approval and commercialization of medical products for European markets. Its diagnostic products include COVID-19 PCR Diagnostic Kit, Peri-Implantitis Oral Biosensor, and H1N1 (Swine Flu) and H5N1 (Avian Flu) Oral Biosensors. Its subsidiaries include XPhyto Laboratories Inc., Bunker Pflanzenextrakte GmbH, Vektor Pharma TF GmbH, BioNxt Europe GmbH, and 3a-diagnostics GmbH, among others.


CSE:BNXT - Post by User

Post by wallpaper2on Mar 10, 2021 12:21pm
104 Views
Post# 32763270

Not so fast!

Not so fast!They could still be weeks away from receiving the 9600 test kits they require to send to any perspective buyers. The perspective buyers will then conduct their own tests before commiting any $$$.
These further tests by perspective buyers will require a few weeks to conduct and analyze. They hope to begin a sales launch sometime in April which by past performance means May or June. They will begin with Germany and try to sell in other countries at a later date.
How many more test kits will hit the market by then and will the vaccinations take the shine off test kits altogether?   Sure, test kits will remain in use but they may be a mere shadow of where they are today.  Regardless of where it ends up the $5 million on interviews etc. should have been spent outsourcing experienced men and women who could have taken it to market months earlier.  jmho
<< Previous
Bullboard Posts
Next >>